6 results about "Primary lesion" patented technology

This invention relates to the field of artificial intelligence in oncology medicine, specifically disclosing a system for quantifying residual tumor burden in gastric cancer, comprising: a data acquisition and interaction terminal, an AI core computing center, and a clinical precision decision support platform; the data acquisition and interaction terminal is configured to acquire in parallel high-resolution digital pathological slides of patients after surgery, continuous physiological time-series characteristic sequences after surgery, and the molecular expression abundance of POU4F1 transcription factor and TGF-β signaling pathway in tumor tissue; the AI ​​core computing center includes a three-dimensional quantification unit for pathological images, a dynamic correction unit for physiological homeostasis, and a molecular phenotypic decision unit; the three-dimensional quantification unit for pathological images is used to automatically segment and obtain the geometric mean diameter of the primary tumor bed, the proportion of residual tumor in the primary lesion, the number of positive lymph nodes, and the proportion of residual tumor in the worst-regressed lymph nodes; the technical solution of this invention can solve the problems of coarse quantification and large subjective bias.

The application relates to the technical field of intelligent medical treatment, and discloses a schistosomiasis laboratory quality management remote consultation system and method based on artificial intelligence. The application effectively solves the problems of weak network transmission congestion, long tail impurity misjudgment and system failure caused by environmental drift that the primary medical institutions face when performing schistosomiasis remote consultation, accurately extracts primary lesion features by dynamically perceiving local optical density changes on the edge side, and under the limited network communication bandwidth, preferentially guarantees high-fidelity lossless push flow of core lesion features, simultaneously implements adaptive degradation and physical truncation on redundant background features, and combines a local cache mechanism to completely eliminate feature space tearing and diagnostic data loss under extremely deteriorated communication environment.

The invention discloses an ovarian endometriosis glandular epithelial organ and interstitial cell co-culture model and a construction method thereof. The construction method comprises the following steps: S1, constructing an ovarian endometriosis cyst glandular epithelial organ; s2, constructing a 3D culture body of the ovarian endometriosis cyst interstitial cells; and S3, digesting the glandular epithelium organ, mixing the glandular epithelium organ with the interstitial cells in proportion, and embedding the glandular epithelium organ in matrigel for three-dimensional co-culture. According to the invention, a patient-derived ovarian endometriosis glandular epithelial organ and interstitial cell co-culture system is established for the first time, the model and a primary focus are highly homologous in tissue morphology and biomarker expression, and the bionic degree is high; it is clear that the number of glandular epithelial organs is the largest when the ratio of epithelial cell clusters to interstitial cells is 1: 2, the vitality of the glandular epithelial organs in a group with the ratio of 1: 2 to 1: 4 is remarkably improved, and the technical bottlenecks that an existing co-culture model is fuzzy in proportion, and the cell viability is difficult to maintain are solved.

The present disclosure relates to the technical field of biological medicine, in particular to a polypeptide targeting PD-L1 and use thereof. The polypeptide provided by the present disclosure has high affinity and good stability. Based on the RDC of the polypeptide, the tumor primary lesion or metastatic lesion can be precisely targeted, and the polypeptide will not be retained in the tissues near the tumor and the tissues in non-tumor parts of the whole body, and the polypeptide can also avoid being rapidly degraded by proteases.

This invention relates to the fields of tumor biology and cell engineering, specifically disclosing the construction and application of a human prostate cancer cell line. The human prostate cancer cell line is derived from primary prostate cancer tissue, expresses prostate-specific antigen and α-methylacyl-CoA racemic enzyme, and has a 46,XY karyotype. The construction method employs an innovative strategy of co-culturing fully digested cell suspensions with incompletely digested tissue blocks, significantly improving the success rate of establishing the cell line from the primary lesion. This cell line can stably proliferate in conventional culture media supplemented with testosterone and has been successfully applied to subcutaneous tumorigenesis models in immunodeficient mice and in vivo migration models in zebrafish. The primary lesion-derived prostate cancer cell line provided by this invention offers a highly relevant, stable, and reliable new experimental tool for studying the biological characteristics of primary prostate cancer, drug screening, and personalized treatment.

The present application relates to the technical field of diagnosis and risk assessment of thyroid papillary carcinoma, and particularly relates to a composition, application and system for preoperative diagnosis and / or risk assessment of thyroid papillary carcinoma. The composition for preoperative diagnosis and / or risk assessment of thyroid papillary carcinoma comprises reagents for measuring the expression level of CLDN16 protein and / or the mRNA expression level of the gene encoding CLDN16 protein. Through the composition, the mRNA expression level of CLDN16 in thyroid tissue can be detected preoperatively, which is used for accurate diagnosis of the primary lesion and metastatic lesion of thyroid papillary carcinoma, and simultaneously, the disease risk of thyroid papillary carcinoma is accurately predicted to guide clinical decision-making.